09-08-2025
Cingulate CEO tells Roth COO departure has no meaningful impact on CTx-1301
After Cingulate (CING) announced the termination of Laurie Myers as COO, Roth Capital caught up with Cingulate Therapeutics' CEO Shane Schaffer to get additional clarity on the 'sudden termination.' The firm's conversation with the CEO suggests the COO's departure has no meaningful impact on the company's near-term strategy or long-term outlook, including the timelines for CTx-1301 FDA approval expected in mid-2026. Following the talks with the CEO, the firm reiterates its Buy rating and $11 price target on Cingulate shares.
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
